MetaVia ObesityWeek poster on DA 1726 arrives with its data still unseen

MetaVia will show DA-1726, its weekly oxyntomodulin analog for obesity and liver disease, at ObesityWeek 2026 in Washington DC. The MetaVia ObesityWeek poster was announced on 9 November, but the company did not say which data it will show. The only efficacy figures in the release are interim Phase 1 results that already sit in its background text. On our board, DA-1726 enters at Phase 1 and the signal stays flat until the poster is public.

What MetaVia announced for ObesityWeek 2026

MetaVia, a Cambridge, Massachusetts company listed on Nasdaq, said an abstract on DA-1726 has been accepted as a poster at ObesityWeek 2026, which runs from 14 to 17 November in Washington DC. The company said a copy will go up in the Posters section of its website after the session. That is the whole of the news. The company announcement gives no abstract title, no session time, no author list and no hint of whether the poster carries fresh numbers or repeats older ones. A poster acceptance is a routine step for a small biotech, and it does not by itself change where a molecule stands. The MetaVia ObesityWeek poster does set a date when outside readers may see more detail on a program that so far rests on interim data.

MetaVia describes DA-1726 as an analog of oxyntomodulin, a natural gut hormone that acts on both the GLP-1 receptor and the glucagon receptor. The company says the drug is built for once weekly injection under the skin and is tuned with a 3:1 potency ratio in favor of the GLP-1 receptor. The aim, as MetaVia puts it, is to pair the appetite and glucose effects of GLP-1 with the energy use and fat breakdown linked to glucagon. Among its risk factors, the release refers to a license agreement with Dong-A ST Co. Ltd. MetaVia is also pairing vanoglipel, a GPR119 drug, with resmetirom for MASH, with a Phase 2a study targeted for the first half of 2027. The table sets out what the company has said.

The interim numbers behind DA 1726

The efficacy figures MetaVia cites come from an interim look at Part 3B of its Phase 1 trial, taken at Day 109. According to the company, DA-1726 cut body weight by 13.5% more than placebo and cut liver fat by 68% more than placebo at that point. MetaVia also reported drops in visceral and subcutaneous fat, with lean mass it calls relatively preserved. The release does not give the number of people in Part 3B, the dose steps used, the spread of results, how liver fat was measured, or side effect and dropout rates. Without those, the figures cannot be weighed against larger trials. A placebo-adjusted result from an early interim cohort is a signal worth following, not a measure of how the drug performs at scale.

A placebo-adjusted result from an early interim cohort is a signal worth following, not a measure of how the drug performs at scale.

Day 109 is also a short window for an obesity drug. Phase 3 weight trials for incretins usually run a year or longer, so an early reading may not match where the curve ends. The liver fat number is the one MetaVia leans on for its plans, since the company is aiming DA-1726 at liver disease linked to alcohol and metabolic risk rather than at obesity alone. The release says preclinical tissue studies showed the drug gathers mostly in fat tissue and the liver, which fits that pitch but comes from laboratory work, not patients. Readers should treat the MetaVia ObesityWeek poster as the first chance to check these interim numbers against fuller detail, if the company chooses to include it.

Where DA 1726 sits among glucagon dual agonists

DA-1726 joins a crowded group of glucagon dual agonist programs. Boehringer Ingelheim's survodutide, a weekly glucagon and GLP-1 dual agonist, is in Phase 3 and recently met its heart safety goal in SYNCHRONIZE-CVOT without showing a benefit. About one in five people on that drug stopped for stomach side effects. Innovent's mazdutide, another molecule acting on both receptors, is listed as approved on our board. Altimmune's pemvidutide sits at Phase 2. Each of these rivals is further along than DA-1726 in patient numbers and trial length. MetaVia's case for a place in the race rests on its 3:1 receptor balance and its liver focus, and neither has been tested head to head against these drugs.

The alcohol angle is where the overlap is closest. Altimmune is taking its Phase 2 alcohol use disorder results to The Liver Meeting and plans to meet the FDA in December about Phase 3, as we reported earlier. MetaVia's chosen target is different: liver disease in people who drink, called ALD, and the overlap of metabolic and alcohol-related liver disease, called MetALD. Both companies are betting that a drug acting on GLP-1 and glucagon receptors can help people whose drinking affects their health. That shared idea is plausible but unproven in outcome trials for either molecule. For now, DA-1726 is the earlier of the two, and the release describes no trial data yet in people with MetALD or ALD.

The MetALD plan and what is still missing

MetaVia says it plans a Phase 2 study of DA-1726 in MetALD and ALD that will last 48 weeks without liver biopsies, and it targets a start in the second half of 2027. That is a company plan, not a scheduled event, and the release gives no size, endpoints, sites or funding detail. A study without biopsies would have to judge the liver through other measures, such as scans or blood tests, and how regulators will view that design for these conditions is not yet known. The release also lists risks common to small biotechs, including a history of net losses and the need to raise more capital. Those caveats matter because a start date more than a year away depends on money as much as on science.

Several things remain unknown before the MetaVia ObesityWeek poster goes up. The release does not say whether the poster shows the Day 109 data, a later Part 3B cut or something else. It gives no safety table, no tolerability detail and no method for the lean mass finding. It also offers no comparison with approved drugs. Readers who want to see how the rest of the field moves can follow the incretin class tracker, where DA-1726 now sits at Phase 1. Our signal is flat because nothing in the molecule's evidence has changed yet. That could shift once the poster appears on the MetaVia website after the meeting, or when the company confirms its Phase 2 design and funding.

Conclusion

The MetaVia ObesityWeek poster is a scheduled look at an early program, not a new result. By the company's account, DA-1726 holds interim Phase 1 figures of 13.5% placebo-adjusted weight loss and a 68% placebo-adjusted cut in liver fat at Day 109. Trial size, safety and durability are still unreported. The molecule stays at Phase 1 with a flat signal, and the next real tests are the poster itself and then the planned Phase 2 start in MetALD and ALD.